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REVIEW
Abstract: Multi-antibiotic resistant Gram-positive cocci, which include Staphylococcus
aureus, the coagulase-negative staphylococcal group, Enterococcus faecalis and Enterococcus
faecium, and other streptococci, represent emerging pathogens especially in the setting of the
immunocompromised, hospitalized patients, in particular when surgery, invasive procedures,
or prosthetic implants are of concern, patients are admitted in intensive care units, or underlying
chronic disorders and immunodeficiency are of concern, and broad-spectrum antibiotics or
immunosuppressive drugs are widely administered. During the recent years, the phenomenon
of multiresistant Gram-positive cocci is spreading to the community, where the retrieval of
such microorganism is progressively increasing. The spectrum of available antimicrobial
compounds for an effective management of these relevant infections is significantly impaired
in selection and clinical efficacy by the emerging and spread of methicillin-resistant and
more recently glycopeptide-resistant Gram-positive microbial strains. The first oxazolidinone
derivative linezolid, together with the recently licensed quinupristin–dalfopristin, daptomycin,
and tigecycline, followed by a number of glycopeptides, fluoroquinolones, and other
experimental compounds on the pipeline, represent an effective response to the great majority
of these concerns, due to their innovative mechanisms of action, their maintained or enhanced
activity against multiresistant pathogens, their effective pharmacokinetic/pharmacodynamic
properties, their frequent possibility of synergistic activity with other compounds effective
against Gram-positive pathogens, and a diffuse potential for a safe and easy administration,
also when compromised patients are of concern. The main problems related to the
epidemiological and clinical features of multiresistant Gram-positive infection, the potential
clinical indications of all recently available compounds compared with the standard of care
of treatment of resistant Gram-positive infections, and updated data on efficacy and tolerability
of linezolid as the golden standard compound for vancomycin-resistant Gram-positive cocci
in multiple clinical situations, are outlined and updated on the ground of an extensive review
of all the available, recent evidences coming from the international literature.
Keywords: resistant Gram-positive organisms, staphylococci, enterococci, oxazolidinones,
linezolid
The rising problem of multiresistant Gram-
positive cocci
Involved microorganisms and risk factors
Since the early eighties, a significant reversal of tendency was observed especially
in hospital settings, characterized by a predominance of Gram-positive over Gram-
negative bacteria (which represented the most relevant concern in the two prior
decades) (Karchmer 2000; Stevens et al 2004; Cunha 2005; Kollef 2005; Menichetti
2005). The increased life expectancy of the general population, the extended survival
of patients with underlyng immunodeficiency and/or chronic disorders, the advances
of surgical techniques and those of invasive diagnostic and therapeutic procedures
and bone marrow and solid organ transplantation, the diffusion of the implant of
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prosthetic materials and other biocompatible materials, and
the increased resort to endovascular catheters and devices
with massive resort to parenteral nutrition techniques, all
of them representing emerging risk factors for a massive
bacterial colonization, which unavoidably turns into an
increased risk of local and systemic infection. At the same
time, the increased and prolonged administration of broad
spectrum antimicrobial agents and their associations, and
the wide employment of potent antimycotic agents, as
therapeutic and/or prophylactic measures directed to manage
the immunocompromised or otherwise at risk host,
extensively contribute to the re-emerging of Gram-positive
pathogens and their increasing resistance rates, especially
via prolonged hospital admissions. Among these
microorganisms, both coagulase-positive and coagulase-
negative Staphylococci, and Enterococci, became of
particular concern in the hospital environment because of
their rising frequency, the severity of associated diseases,
and the unpredictable spectrum antimicrobial extend
resistance (Wenzel and Edmond 1998; Karchmer 2000;
Linden 2002; Cunha 2005; Kollef 2005; Menichetti 2005;
Segreti 2005; Pace and Yang 2006). This is also increasingly
true in the pediatric population, as recently confirmed by
the literature (Cunha 2005; Ladhani and Garbash 2005;
Marcinak and Frank 2006).
Finally, the progressive shortening of hospitalization
favors the spread of hospital-acquired, nosocomial
pathogens into the community, where there is increasing
concern for the rising retrieval of microorganisms with a
resistance pattern similar to that observed at the hospital,
which may be responsible for an increasing failure of initial,
empiric therapeutic lines, when antimicrobial agents are
administered before obtaining culture and in vitro resistance
testing, or when cultures and antimicrobial susceptibility
testing are pending or not available (Cunha 2005; Ellis and
Lewis 2005; Menichetti 2005; Marcinak and Frank 2006;
Pace and Yang 2006).
Together with the ever-evolving modification of the
above-mentioned multiple environmental conditions, the
changing features of both host and its microbial flora, and
the broadened spectrum of currently available antiinfective
compounds, other emerging features become prominent,
related to the pathomorphism of clinical features of a number
of infections caused by Gram-positive pathogens, often
those which share an evident potential for the development
and spread of antimicrobial resistance. When considering
Staphylococci, the major pathogen Staphylococcus aureus
steadily ranks at the first place among the majority of
hospital-acquired pathogens, and novel syndromes
characterized by the predominant role of bacterial toxemia
are progressively emerging: the so-called staphylococcal
scalded skin syndrome (or SSSS) is the paradigmatic clinical
picture. Moreover, severe staphylococcal skin and soft tissue
lesions have been increasingly attributed to the action of
the staphylococcal Panton-Valentine leukocidin (Marcinak
and Frank 2006). Remarkable levels of morbidity and
mortality are also attributed to coagulase-negative cocci (ie,
Staphylococcus epidermidis and related organisms),
especially when vascular or bone-joint prosthetic devices,
central vascular lines, ventilator-associated pneumonia, and
total parenteral nutrition are of concern. Until a couple of
decades ago, the same coagulase-negative staphylococci
were usually considered as part of the normal saprophytic
human flora, or trivial local contaminants. On the other hand,
while streptocococcal scarlet fever, and post-streptococcal
complications like rheumatic disease and acute
glomerulonephritis virtually disappeared in the past two
decades, a number of other disorders caused by highly
pathogenic Streptococci gained increasing frequency and
importance in the last decades, including severe cellulites,
necrotizing fasciitis, and the so-called toxic shock syndrome
(TSS).
Incidence of severe Gram-positive
infections caused by multiresistant
pathogens
In the industrialized countries of the planet, the rate of
methicillin (oxacillin) resistance of Staphylococci among
hospitalized patients may overcome 20%–25% of cases,
with an extremely elevated frequency registered in
specialized intensive care units and bone marrow and solid
organ transplant units (Edmond et al 1999; Karchmer 2000;
Manfredi et al 2004; Cunha 2005; Kollef 2005; Segreti
2005). A relevant multicentre survey of nosocomial
bacteremia carried out in 49 hospitals of the US during three
consecutive years, allowed the authors to recognize a 64%
prevalence of Gram-positive pathogens, among over 10 000
identified microorganisms (Edmond et al 1999). When
analyzing the frequency of each single microorganisms in
this study, coagulase-negative Staphylococci (32%)
preceded S. aureus (16%), and Enterococci as a whole
(11%). The overall level of methicillin resistance ranked
around 29% of isolated organisms, with peaks reaching 80%,
when coagulase-negative Staphylococci were specifically
considered (Edmond et al 1999).Therapeutics and Clinical Risk Management 2006:2(4) 457
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In a S. aureus prevalence study carried out in Spain, an
overall increase in resistance to the majority of antimicrobial
agents was detected, mainly involving oxacillin (from a
frequency ranging from 1.5% and 32.5% in the year 1986,
to 31.2% and 61.3% respectively in the year 2002), although
all isolates remained susceptible to all the available
glycopeptides, quinupristin–dalfopristin, and linezolid, and
a surprisingly low resistance rate was found when examining
cotrimoxazole (0.5% to 2.1%) (Cuevas et al 2004). Also
other studies noticed this somewhat elevated cotrimoxazole
susceptibility (Bishara et al 2003; Roberts and Chambers
2005).
A similar phenomenon was observed at a large teaching
hospital in Taiwan, where the noticeable rise of methicillin-
resistant Staphylococci and vancomycin-resistant
Enterococci paralleled the increased prescription of
glycopeptides, broad-spectrum beta-lactams, carbapenems,
and fluoroquinolones, during recent years (Hsueh et al
2005).
Among these microorganisms which share a
predominant nosocomial isolation, the appearance of
methicillin resistance is usually linked to an almost complete
lack of in vitro susceptibility to all beta-lactam antibiotics,
but usually it extends to macrolides, lincosamides, and a
large part of aminoglycosides and fluoroquinolones,
therefore leading to a very striking reduction of remaining
therapeutic options (Wenzel and Edmond 1998; Lamb et al
1999; Karchmer 2000; Linden 2002; Stevens et al 2004;
Cunha 2005; Kollef 2005; Menichetti 2005; Segreti 2005;
Pace and Yang 2006). Notwithstanding that the frequently
concurrent pathophysiological conditions can also act
unfavorably, by limiting both microbiological and clinical
efficacy of an antimicrobial treatment in vivo (Table 1),
however the selection and spread of pharmacoresistant
bacterial strains represents the main feature responsible for
their greatly reduced activity in current clinical practice.
Guidelines for the management of
resistant Gram-positive infections, and
emerging of glycopeptide resistance
The present recommendations for empiric antimicrobial
chemotherapy of the immunocompromised and/or
neutropenic patient take into careful account of the
ethiological shift from Gram-negative towards Gram-
positive organisms which occurred during the past 20 years.
In the past decade, the guidelines for empiric antibiotic
therapy of at-risk patients strongly recommended the adjunct
of drugs which are highly active against methicillin-resistant
Gram-positive cocci, but concomitantly contributed to the
appearance and further spread of mutant microbial strains,
which may test either “intermediate” or are even “resistant”
to both available glycopeptides (vancomycin and
teicoplanin). In fact, these last compounds (vancomycin and
teicoplanin) represented the “gold-standard” therapeutic
reference for the management of multiresistant Gram-
positive cocci, until a few years ago (Karchmer 2000; Linden
2002; Manfredi et al 2004; Stevens et al 2004; Akins 2005;
Cunha 2005; Kollef 2005; Menichetti 2005; Segreti 2005;
Pace and Yang 2006). However, an extensive Italian survey
over 1997–1998 (Nicoletti et al 2000), showed that Gram-
positive microorganisms were responsible for slightly more
than 50% of respiratory infection and septicemia identified
in three different Italian intensive care units, with absolute
predominance of S. aureus (29.2%), followed by coagulase-
negative Staphylococci (9.5%), Streptococcus pneumoniae
(4.1%), and Enterococcus faecalis (2.9%). Methicillin-
resistance levels tested around 46% for S. aureus, but rose
to 64% for coagulase-negative Staphylococci (Nicoletti et
al 2000).
When evaluating the episodes of nosocomial sepsis, the
international “SCOPE” study carried out in 1998 by the
SCOPE Hospital Study Group (Marshall et al 1998)
attributed the greatest incidence to coagulase-negative
Staphylococci, followed by S. aureus and Enterococcus spp.,
whose mortality rates proved 21%, 25%, and 32% of
reported cases, respectively. Enterococcus spp. organisms
showed an antimicrobial susceptibility pattern notably
different between E. faecalis and E. faecium: this last
pathogen (ie, E. faecium) was increasingly identified during
recent years in association with methicillin resistance levels
often greater than 50% of tested strains. Concurrently, the
incidence of methicillin resistance among coagulase-
negative Staphylococci (with S. epidermidis always
representing the leading organism of the group), tested even
greater in frequency (also over 60%–80% in different
clinical settings) (Pace and Yang 2006).
Finally, an fierce discussion is still ongoing regarding
the role and frequency of staphylococcal strains which test
“intermediate” to vancomycin and glycopeptides in general
(the so-called “glycopeptide-intermediate S. aureus”
[GISA]), which were identified in Japan in 1996
(Anonymous 1997). The incidence of this last phenomenon
is estimated to be still geographically contained, although
it is more commonly recognized in countries where the
frequent resort to the administration of glycopeptideTherapeutics and Clinical Risk Management 2006:2(4) 458
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antibiotics supported a non-specific selective pressure over
the relevant microorganims. The spread of glycopeptide
(vancomycin–teicoplanin) resistance may occur through
different bacterial species especially in the gastrointestinal
tract, which may act as a reservoir of genes conferring
resistance to glycopeptides and concurrently to many other
antimicrobial compounds (Lipski et al 2004; Stevens et al
2004; Menichetti 2005; Segreti 2005; Pace and Yang 2006).
The potential contribution of the
novel oxazolidinone derivative:
linezolid
Selected pharmacological issues
Linezolid represent the first member of a novel class of
oxazolidinone derivatives (a, q), which encompasses an
effective activity spectrum which covers all the most
important Gram-positive organisms, including those
resistant to methicillin and glycopeptides. The chemical
structure of linezolid is sketched in Figure 1. The
oxazolidinones have an unique mode of action, which
inhibits the initiation of the synthesis of bacterial proteins
and enzymes, by preventing the formation of the ternary
complex at 70S ribosomal subunit (Stevens et al 2004), by
an apparent double blockade of both the 50S and the 30S
bacterial ribosomal subunits. The uniquely particular
mechanisms of action of linezolid, which includes a
blockade of ribosomal assemblation which occurs before
the initiation of bacterial protein synthesis (Stevens et al
2004), makes very improbable the emerging of cross
resistance with other antimicrobial compounds. Single
episodes of linezolid resistance have until now been
anecdotally reported, especially after long-term and low-
dosage courses, although it appears to be extremely rare
among Staphylococci (Herrero et al 2002; Meka and Gold
2004), while linezolid-resistant Enterococci have been
occasionally reported in intensive care units (Weigelt et al
2005), reports for both are now increasingly common.
From a pharmacokinetic point of view, linezolid is
protein-bound for around 30%, and this molecule favorably
penetrates at elevated and fully active concentrations into a
broad variety of tissues, such as fat, bone and joints, muscle,
cerebrospinal fluid and wound sites, beyond the known,
elevated penetration into the lungs and the entire respiratory
tract (Eliopoulos 2003; Stevens et al 2004). The drug
Table 1 Factors which contribute at various levels to the choice of empirical or selective antimicrobial chemotherapy, when
resistant Gram-positive cocci may be of concern
- Local epidemiology maps, and hospital epidemiology (nosocomial) maps
- Ethiological diagnosis and in vitro antimicrobial susceptibility assays
- Patient’s conditions and eventual underlying disorders and supporting conditions
- Patient’s status of immune competence
- Predisposing conditions
- Appropriate physician’s prescription
- Spectrum of activity of prescribed antimicrobial agents, and their eventual association (to exploit additive or synergistic activity)
- Drug bioavailability characteristics (including drug disposition and diffusion, protein link, volume of distrubution, tissue and intracellular
penetration, pharmacokinetic and pharmacodynamic properties)
- Serum and tissue half-life of selected compounds
- Expected or assessed antimicrobial resistance pattern
- Drug metabolism, eventual post-antibiotic effect, elimination routes
- Peak levels, minimal inhibitory concentrations (MIC), mimimal bactericidal concentrations (MBC), area under the curve (AUC), and related
pharmacokinetic/pharmacodynamic parameters
- Drug–drug interactions (increased or reduced activity and toxicity), drug metabolism (active or inactive metabolites)
- Comprehensive duration of antimicrobial chemotherapy courses
- Comprehensive tolerabilily, and toxicity issues in otherwise healthy, or compromised subjects
- Patient’s compliance (also related to eventual concomitant pharmacological treatments)
- Crude and comprehensive costs of administration and delivery of each single drug in the relevant context (including possibility to switch from
a parenteral to an oral route of administration)
- Comprehensive pharmacoeconomic issues
Figure 1 Chemical structure of linezolid, the first oxazolidinone antimicrobial
compound. The first ring (from the left) contains a morpholino group, which
enhances its pharmacokinetic profile and improves water solubility. In the
second ring (from the left), the strategically located fluorine atom enhances drug
activity. The “bridge” structure after the third ring (from the left) bears a
necessary 5-(S) configuration. The terminal (right) C-5 acylaminomethyl group is
essential for ensuring the unique drug characteristics.Therapeutics and Clinical Risk Management 2006:2(4) 459
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metabolism is not affected by the cytochrome P450 pathway,
so that drug–drug interactions at this setting are not expected.
Some selected pharmacokinetic properties of linezolid when
administered intravenously compared with oral route (at
standard dosages) are listed in Table 2.
Being formulated for both the intravenous (IV) and the
oral route of administration, linezolid retains a 100%
bioavailability even after oral administration (Eliopoulos
2003; Stevens et al 2004), and regardless of meals, therefore
making it easier to exploit the oral administration for
switching therapies and early discharge from the hospital
of patients who can be effectively followed on a Day-
Hospital outpatient basis, and also to directly start
antibacterial therapy by oral route, whenever possible. All
the above-mentioned aspects have a significant amount of
favorable consequences, when comprehensive morbidity
and mortality rates, overall length of hospital stay, and
increased medical expenses are considered, even when
compared with the proportionally elevated costs attributable
to linezolid therapy (Moellering 2003; Stevens et al 2004).
Microbiological properties, clinical
studies, and clinical indications
After expanded-access studies which included seriously ill
patients suffering from multidrug-resistant, Gram-positive
infections in situations also encompassing bacteremia (46%
of 796 cases), endocarditis, and catheter-related infection
(Birmingham et al 2003), at its first approval in the US,
linezolid was initially registered for the treatment of both
community-acquired and nosocomial pneumonia,
uncomplicated and complicated skin and soft tissue
infections (including diabetic foot infections and surgical
wound infection), and infectious caused by methicillin- and
vancomycin-resistant Staphylococci and Enterococci, and
penicillin-resistant and macrolide-resistant Streptococci and
Pnemococci, including episodes complicated by bacteremia
(Moellering 2003).
Since ribosomal mutations have been detected which
may induce resistance against linezolid, longitudinal
surveillance surveys remain needed to strictly monitor this
phenomenon. The 2003 Zyvox Annual Appraisal of Potency
and Spectrum (ZAAPS) program, compared the MIC90
levels of linezolid with 13–15 comparator agents in over
8000 bacterial isolates (Anderegg et al 2005), and confirmed
a maintained 99.93% linezolid susceptibility rate of tested
Gram-positive organisms, as previously predicted (Meka
and Gold 2004). The recently published continuation of this
study until 2004 (Jones et al 2006) confirmed this figure on
even 20 158 overall tested isolates, pointing out that 99.5%
of isolated S. aureus organisms had a MIC90 value of
linezolid ranging from 0.5 mg/L to 2 mg/L, with only one
bacterial  strain  tested  susceptible  only  at  a  MIC90  value
of 4 mg/L (Jones et al 2006).
In particular, when considering complicated skin and
soft tissue infections, a randomized, open study has been
conducted on 1200 hospitalized patients with confirmed or
suspected methicillin-resistant staphylococcal isolates
(Sharpe et al 2005). The most common disorders were
represented by severe cellulitis (46%), cutaneous abscess
(26%), and surgical wound infection (11%). In the intention-
to-treat comparison between linezolid (given at 600 mg IV
twice daily) and vancomycin (at 1 g IV twice daily), the
cure rate was 92.2% versus 88.5% respectively (p=0.057),
while involed pathogens included methicillin-resistant
Staphylococci in 42% of cases, followed by methicillin-
sensitive Staphylococci (29%), and coagulase-negative
Staphylococci (8%) (Sharpe et al 2005). When considering
methicillin-resistant staphylococcal infections only, a greater
percentage of success rate was obtained with linezolid over
vancomycin (88.6% vs 66.9% respectively; p<0.001),
paralleling the better bacteriological success rate of linezolid
over vancomycin (p<0.001) (Sharpe et al 2005). In a subset
of the above-mentioned study including surgical site
infections presumably due to methicillin-resistant
Staphylococci, although the clinical cure rate proved similar,
linezolid obtained a greater bacteriological eradication rate
(p<0.008), and a higher rate of microbiological cure
(p<0.003) (Sharpe et al 2005). In an open study of
complicated staphylococcal skin and soft tissue infections,
oral linezolid and IV vancomycin were compared at the same
dosage regimens for 7–21 days, and a higher clinical
response was obtained with linezolid (p<0.02), associated
with a lower rate of failure leading also to a resort to major
Table 2 Mean multiple-dose pharmacokinetics of linezolid,
administered twice daily, as recommended (modified from
Stevens et al 2004)
Parameter 600 mg oral tablet 600 mg IV
Cmax (mcg/mL) 21.2 ± 5.78 15.10 ± 2.52
Cmin (mvg/mL) 6.15 ± 2.94 3.68 ± 2.36
Tmax (hours) 1.03 ± 0.62 0.51 ± 0.03
AUC (mcgh/mL) 138.0 ± 42.1 89.7 ± 31.0
Half-life (hours) 5.40 ± 2.06 4.80 ± 1.70
Clearance (mL/min) 80.0 ± 29.0 123.0 ± 40.0
Abbreviations: AUC, area under the curve.Therapeutics and Clinical Risk Management 2006:2(4) 460
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surgical procedures, ie, limb amputation (p<0.02)
(Rubinstein et al 2001). Later, Weigelt and colleagues (2005)
assessed linezolid versus vancomycin in the treatment of
complicated skin and soft tissue infections in a randomized
trial, but an evident overall superiority of linezolid was not
reached from a statistical point of view.
Moreover, lower respiratory infections and pneumonia
were assessed in two large, multicentre, randomized, double-
blind trials conducted on 1019 patients on the whole,
affected by a nosocomial pneumonia presumably due to
Gram-positive organisms (Wunderink et al 2003; Wilcox et
al 2004). In these studies, an empirical linezolid treatment
proved comparable with a vancomycin one, from both an
efficacy and safety point of view (Wunderink et al 2003;
Wilcox et al 2004). In a subgroup which included 123
patients with a confirmed hospital-acquired methicillin-
resistant staphylococcal pneumonia, a greater survival rate
(84% vs 62%; p=0.02), and clinical cure (62% vs 21%;
p<0.001) were achieved with linezolid, compared with
vancomycin. In another study (Nathwani et al 2004) which
compared the efficacy of linezolid and teicoplanin in 430
patients with differently located, ascertained or presumed
Gram-positive infections, linezolid proved as effective as
teicoplanin in patients suffering from pneumonia (96% vs
93%), but infections complicated by bacteremia had a
greater response rate when linezolid was administered
(88.5% vs 56.7%; p<0.001) (Nathwani et al 2004). Finally,
the increased and proven recognition of the clinical potential
of linezolid led to the inclusion of this novel oxazolidinone
derivative in the treatment guidelines of the American
Thoracic Society and those of the Infectious Disease Society
of America (IDSA), as an empirical, initial choice for
patients with a suspected nosocomial pneumonia caused by
methicillin-resistant Staphylococci, or where the local,
global prevalence of these organisms is known to be elevated
(Moellering 2003; Craven et al 2004).
In adjunct, smaller patient series and anecdotal case
reports of linezolid use in other relevant infectious processes
are increasing day by day. The excellent tissue penetration
of linezolid makes this oxazolidinone drug extremely
promising for the approach to difficult-to-treat endocarditis
with or without bacteremia (Hill et al 2006), central nervous
system infections (Castro et al 2005; Sabbatani et al 2005;
Manfredi et al 2006), and bone and joint infections
(Manfredi et al 2005; Barberan 2006), caused by resistant
Gram-positive cocci. Randomized clinical experiences are
strongly expected to enforce eventual linezolid indications
in these difficult-to-treat infections.
In the meantime, also pediatric experiences with
linezolid are increasing day by day (Eliopoulos 2003;
Ladhani et al 2005; Marcinak and Frank 2006).
A combination therapy of linezolid with other
antimicrobial compounds is indicated when the co-existence
of Gram-negative pathogens is ascertained or suspected.
Moreover, a very interesting activity of linezolid has been
demonstrated both in vitro and in vivo against susceptible
and especially multi-drug resistant Mycobacterium
tuberculosis (Alcala et al 2003; Erturan and Uzun 2005;
Fortun et al 2005), and a synergistic activity may be
exploited with a broad spectrum of fluoroquinolones
(Rodriguez Diaz et al 2003; Barberan 2006), although the
clinical significance of those associations needs to be
clinically confirmed by controlled clinical trials.
Tolerability and safety issues
From a tolerability point of view, within the maximum
allowed treatment duration of 28 days (as presently
recommended), linezolid showed a favorable safety profile,
as showed in a very extensive meta-analysis of 2046 adult
patients enrolled in seven different comparative, controlled
studies (Moellering 2003; Bressler et al 2004). The 85% of
reported adverse events was mild-to-moderate in intensity:
the most common clinical events were diarrhea (4.0% to
5.3%), nausea (3.3% to 3.5%), and headache (1.9% to 2.7%),
while the most common laboratory disturbances included
anemia and thrombocytopenia, especially when linezolid
treatment is prolonged, as in some experimental indications,
like bone and joint infections (Moellering 2003; Bressler et
al 2004; Craven et al 2004; Senneville et al 2005).
During the post-marketing surveillance, sparse cases of
neuritis (also including sparse cases of optical neuritis), and
lactic acidosis were anecdotally reported, especially when
linezolid treatment was extended beyond four weeks
(Nasraway et al 2003; Kopterides et al 2005). Also
myelotoxic effects and thrombocytopenia (whose
pathogenesis still remains unknown) were associated with
prolonged treatment durations, although some reports
showed a somewhat earlier appearance. However, the risk
of clinically significant thrombocytopenia as assessed on
686 patients with nosocomial pneumonia treated with
linezolid for at least five days was limited to 6.4% (compared
with 7.7% observed in the comparative vancomycin group)
(Moellering 2003; Salyers et al 2004; Stevens et al 2004).
When chronic or acute kidney insufficiency or hemodyalisis
or hemofiltration are of concern, no correction of linezolid
dosage are needed (Fiaccadori et al 2004), as compared withTherapeutics and Clinical Risk Management 2006:2(4) 461
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the limitations which become necessary when glycopeptide
antibiotics (vancomycin or teicoplanin) are administered
(Eliopoulos 2003; Craven et al 2004). However, an
accumulation of linezolid metabolites has been observed in
patients with renal impairment. Therefore, the selection of
linezolid appears more indicated when a co-existing renal
insufficiency may hamper the use of glycopeptides and other
drugs with an increased renal toxicity. Finally, the well
known activity exerted by linezolid on the inhibition of
monoamine oxidase may prompt potential adverse drug–
drug interactions with a broad range of antidepressant
medications, which has to be carefully taken into account
when facing patients who receive complex, multiple
pharmacological treatments (Clark et al 2006; Lawrence et
al 2006; Sola et al 2006).
Preliminary pharmacoeconomic
assessments
A relevant European study (Rubinstein et al 2003)
considered 227 patients with serious Gram-positive
infections, treated with linezolid compared with teicoplanin,
and assessed hospital resource use and overall treatment
costs. The enrolled patients were randomized according to
a 50:50 ratio to receive either linezolid for 7 to 28
consecutive days (initially by IV route, but with the
possibility to shift to the oral administration as soon as
possible), or teicoplanin (initially by IV administration,
potentially followed by intramuscular route) (Rubinstein et
al 2003). The mean IV treatment duration was 3.2-days
shorter in the linezolid group (6.3 vs 9.5 days), tending to
lead to a reduction of overall hospitalization costs, when
comparing the novel oxazolidinone linezolid even against
the most expensive glycopeptide teicoplanin (Moellering
2003; Rubinstein et al 2003).
Although the efficacy and safety of linezolid have been
well demonstrated and checked in serious, high-risk and
life-threatening infections where multiresistant Gram-
positive cocci are involved, and multiple pharmacoeconomic
appraisals show that the availability of a bioequivalent oral
formulation and a rapid switch therapy from intravenous to
oral route of administration, may effectively counterbalance
the more elevated crude costs compared with older
glycopeptides like vancomycin, however further controlled
clinical trials are strongly needed to expand the indications
of this promising antibiotic, and to check carefully its
tolerability in more extensive patient populations and
baseline conditions (ie, extreme life ages, comorbidity, drug–
drug interactions, and so on) (Moellering 2003). A short
summary of some key issues in the pharmacoeconomic
evaluation of a costly drug address to save from life-
threatening infection is contained in Table 3.
A ponderate prescription of linezolid limited to selected
cases of serious, resistant Gram-positive infections,
associated with improved standards of control and
monitoring of nosocomial infections, are expected to add
significantly to the long-term planning of effective
guidelines of prescription, and large-scale resource
allocation, in the optimization process of the management
of multiresistant Gram-positive infection in critical care
settings.
Need of confirmations and future
developments
The proportionally recent availability of linezolid and other
novel agents devoted to the fight against glycopeptide-
resistant Gram-positive cocci (ie, quinupristin–dalfopristin,
daptomycin, and others), determined significant changes in
the scenario of the management of severe infections due to
multiresistant Gram-positive pathogens, usually acquired
at the hospital and by a somewhat immunocompromised
host (Abbanat et al 2003; Akins et al 2005; Hancock 2005;
Segreti 2005).
A recent, extensive survey conducted on 258 Gram-
positive bacterial organisms isolated from blood cultures at
an US cancer reference centre allowed to compare for the
first time the in vitro acitivity of daptomycin, linezolid, and
quinupristin–dalfopristin (Smith et al 2005). Vancomycin-
resistant Enterococci represented the largest proportion of
tested organisms (32%), followed by methicillin-resistant
coagulase-negative Staphylococci (23%), and vancomycin-
Table 3 Pharmacoeconomic variables of antimicrobial agents
to be evaluated, especially when when an agent burdened by a
proportionally elevated crude cost has to be addressed
(modified from Nathwani 2006)
OVERALL EXPENDITURES
- Direct
- Indirect
- Intangible ones
TIME HORIZON CONSIDERED
- Short-term
- Medium-term
- Long-term
DIFFERENT PERSPECTIVES
- Society
- Patient
-P a y e r
- ProviderTherapeutics and Clinical Risk Management 2006:2(4) 462
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sensitive Enterococci (14%). Through a detailed analysis
of both MIC and mimimal bactericidal concentrations
(MBC) values, daptomycin showed a bactericidal activity
against the majority of tested organisms, by killing almost
100% of bacteria within six hours. Quinupristin–dalfopristin
was bactericidal against Staphylococci and bacteriostatic
against the majority of Enterococci. Linezolid was
bacteriostatic against all evaluated organisms, but a
correlation between the in vitro features and the clinical
outcome demonstrated an elevated potential of all these
novel compounds (Smith et al 2005), which now deserve
controlled studies in the setting of the management and
prevention of serious infection in the immunocompromised
host, including HIV/AIDS patients, subjects with
hematologic malignancies or solid tumors, and those
undergoing bone marrow or organ transplantation, or major
surgery and hospitalization in intensive care units.
Interestingly, a recent study also pointed out a significant
reduction of acute-phase proinflammatory cytokines from
human peripheral mononuclear cells (Garcia-Roca et al
2006) when linezolid was administered, thus confirming
an immunomodulating response to linezolid use.
Conclusions and future
developments and expectations
The overall appraisal of the epidemiology and virulence of
community-acquired multiresistant Gram-positive
pathogens continue to grow, leading to major attention
devoted to developing compounds, but also a re-examination
of many older, but still active agents (including long-acting
tetracyclynes, fluoroquinolones, rifampicin, cotrimoxazole,
and clindamycin) (Moellering 2003; Craven et al 2004;
Manfredi et al 2004; Shah 2005; Schmidt-Ioanas et al 2005),
which certainly retain some non-negligible therapeutic role,
especially when a synergistic activity can be demonstrated
(Akins et al 2005; Ellis and Lewis 2005). Moreover, through
novel laboratory assays like the so-called E-test synergy
and time-kill methods will perhaps become possible to
measure to extent of synergistic activity between differently
combined molecules against glycopeptide-resistance gram-
positive cocci (ie, daptomycin and rifampicin against
multiresistant Enterococci) (LaPlante and Rybak 2004;
Hancock 2005; Shah 2005; Tsuji et al 2006).
As summarized above, future therapeutic research
promises the development of novel compounds aimed at
intervening favorably against the unavoidable increase of
drug resistance frequency and levels against the present
reference compounds (ie, the glycopeptides vancomycin and
teicoplanin) (Pace and Yang 2006), and later the two above-
mentioned recent molecules, ie, quinupristin–dalfopristin
and especially linezolid (Linden 2002; Abbanat et al 2003;
Meka and Gold 2004; Akins et al 2005; Menichetti 2005;
Schmidt-Ioanas et al 2005; Segreti 2005; Barberan 2006).
Some relevant issues regarding linezolid, compared with
the present standards of care (vancomycin and teicoplanin),
and two recent comparators (quinupristin–dalfopristin and
daptomycin), are summarized in Table 4.
On the other hand, the clinical use of the streptogramin
combination quinupristin–dalfopristin, which retains
Table 4 Some key mode and resource use with antimicrobials specific for resistant Gram-positive infections. Linezolid compared
with standard of care antimicrobials for methicillin-resistant Gram-positive cocci infections (vancomycin and teicoplanin), and with
the currently available alternatives recently introduced into the market (quinupristin/dalfopristin, and daptomycin)
Linezolid Vancomycin Teicoplanin Quinupristin/ Daptomycin Tigecycline Dalbavancin
dalfopristin
IV and oral route, Yes No* No* No No No No
both available
Ambulatory Yes No Yes Yes? ? ? Yes
(outpatient)
administration
feasible
Need of serum No Yes No Yes Yes? No No
drug level
monitoring
Frequency of drug
administration Twice daily At least twice Once daily Once daily Once daily Twice daily Once weekly
daily, to 24 h
continue infusion
Abbreviations: IV, intravenous.
Note: *indication restricted to the management of Clostridium difficile-associated diarrhea.Therapeutics and Clinical Risk Management 2006:2(4) 463
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optimal activity against methicillin-resistant S. aureus and
vancomycin-resistant E. faecium, is limited because of its
need to be administered in large volume of fluids (Shah
2005), while its activity in severe pneumonia is somewhat
lower, therefore it is not strongly indicated (Manfredi et al
2004). The oxazolidinone linezolid is active against
methicillin-resistant Staphylococci and glycopeptide-
resistant Enterococci, but resistant organisms and sparse
treatment failures have been reported (Shah 2005), while
unexpected, recent tolerability issues are becoming of
concern (Kopterides et al 2005).
Finally, we have to remind that in many cases the most
relevant therapeutic intervention for complicated Gram-
positive abscesses, cellulitis, complicated skin and soft tissue
diseases, but also osteomyelitis, infected bone and joint
prostheses, and brain abscesses, remains an adequate
surgical drainage and curettage of purulent fluid collections,
and the elimination of affected, necrotic tissue (Ellis and
Lewis 2005; Shah 2005; Barberan 2006). Subsequently, the
antimicrobial selection should be driven by disease severity,
susceptibility patterns, clinical response to therapy, and also
related costs (seen from a comprehensive point of view).
Also special population such as the pediatric and neonatal
ones (Lahdani et al 2005), are going to benefit from
specifically-designed trials, which could address future
issues in the setting of epidemiology, mechanisms of
virulence, continued changes in pathogenicity and
antimicrobial susceptibility of involved organisms, and
potential use of novel antimicrobial compounds.
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